Nanoparticle

Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

Retrieved on: 
Wednesday, January 24, 2024
Death, Neoplasm, Patient, Nanoparticle, Therapy, Ras GTPase, RNA, Small RNA, Cancer, NSCLC, Mutation, IND, Lung cancer, FDA, Investigational New Drug, CRC, Clinical trial, Colorectal cancer, Patent, RAS, American Cancer Society

HAMILTON, BERMUDA, Jan. 24, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has filed a second provisional patent application with the United States Patent and Trade Office (USPTO) to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company’s OligoPhore™ platform and a single siRNA sequence, polyKRASmut. The nanoparticles are developed by Altamira as AM-401.

Key Points: 
  • The second provisional application contains in vitro data confirming the ability of polyKRASmut siRNA to knock down a broad range of KRAS mutations in cancer cell lines.
  • Since polyKRASmut was tested against only a limited number of mutations, it may potentially knock down other, yet untested mutations.
  • “By combining the polyKRASmut siRNA with our OligoPhore platform we can direct its delivery to the tumor and tackle with one single compound many different KRAS mutations.
  • Only recently, the FDA approved the first two treatments for KRAS-driven cancer: sotorasib and adagrasib, two small molecule inhibitors of G12C-mutated KRAS for the treatment of NSCLC.

GenEdit Announces Multiyear Collaboration and License Agreement with Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease

Retrieved on: 
Tuesday, January 23, 2024
Science, Biotechnology, Nanotechnology, Research, Pharmaceutical, Health, Technology, Genetics, Roche, Autoimmune disease, Nanoparticle, Autoimmunity, Genentech, Therapy, Vaccine

GenEdit, Inc. , a developer of genetic medicines that leverage its NanoGalaxy® platform for tissue-selective delivery, today announced a multiyear collaboration and license agreement with Genentech, a member of the Roche Group.

Key Points: 
  • GenEdit, Inc. , a developer of genetic medicines that leverage its NanoGalaxy® platform for tissue-selective delivery, today announced a multiyear collaboration and license agreement with Genentech, a member of the Roche Group.
  • The companies will employ GenEdit’s NanoGalaxy platform to discover and develop novel nanoparticles to deliver Genentech’s nucleic acid-based medicines for treatment of autoimmune disease.
  • “We are excited to work with Genentech to develop novel therapeutics for autoimmune disease,” said Kunwoo Lee, Ph.D., CEO of GenEdit.
  • “Genentech is a leader in advancing breakthrough science to advance the development of novel therapeutic modalities.

Alaya.bio announces significant collaboration with leading global cancer center to advance in situ CAR-T Therapy

Retrieved on: 
Thursday, January 18, 2024
Biotechnology, Pharmaceutical, Health, Patient, Nanoparticle, Cell engineering, Research, CSO, Bone marrow, MSK, Doctor of Philosophy, Cell, Messenger, Gene editing, Pharmaceutical industry

The collaboration will advance research into in situ CAR-T cell therapies and evaluate their potential to deliver faster, more effective, and cost-efficient treatments for patients.

Key Points: 
  • The collaboration will advance research into in situ CAR-T cell therapies and evaluate their potential to deliver faster, more effective, and cost-efficient treatments for patients.
  • The collaboration with the Sadelain lab includes a license agreement and a sponsored research agreement.
  • Over the coming two years the Sadelain lab will lead activities to advance Alaya.bio’s polymeric delivery platform into the clinic in a chosen hematological malignancy.
  • This innovative approach guarantees stable expression of the CAR transgene and preserves transduced T-cells from exhaustion, two crucial features for long-term clinical benefit.

Global Cerium Oxide Nanoparticles Market Outlook 2022-2035: Environmental Concerns Drive Adoption, Dispersion Form Dominates, Cosmetic Industry's Demand Spurs Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 17, 2024
Chemicals, Plastics, Manufacturing, Cerium, Nanoparticle, Market value, Application, Form, Cosmetics, Catalysis, USD, Biomedicine, Prevalence, Cardiovascular disease, Energy, Growth, Automotive industry

The "Global Cerium Oxide Nanoparticles Market Outlook 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cerium Oxide Nanoparticles Market Outlook 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • The global cerium oxide nanoparticles market is anticipated to grow with a CAGR of 19% over the forecast period, i.e., 2023-2035.
  • The global cerium oxide nanoparticles market is segmented into numerous segment which includes, form and application.
  • Market Value (USD Million), Volume (Tons) Current and Future Projections, 2022-2035
    Market Increment $ Opportunity Assessment, 2022-2035
    Global Cerium Oxide Nanoparticles Market Valuation, Business Viewpoint, and Forecast by Form, 2022-2035
    Dispersion, Market Value (USD Million), Current and Future Projections, 2022-2035
    Powder, Market Value (USD Million), Current and Future Projections, 2022-2035
    Global Cerium Oxide Nanoparticles Market Valuation, Business Viewpoint, and Forecast by Application, 2022-2035
    Biomedical, Market Value (USD Million), Current and Future Projections, 2022-2035
    Sunscreen Cosmetics, Market Value (USD Million), Current and Future Projections, 2022-2035
    Energy, Market Value (USD Million), Current and Future Projections, 2022-2035
    Catalyst, Market Value (USD Million), Current and Future Projections, 2022-2035
    Others, Market Value (USD Million), Current and Future Projections, 2022-2035

MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.

Retrieved on: 
Wednesday, January 17, 2024
Magnetic resonance, CMC, Syndrome, Patient, Cirrhosis, Hepatitis, Nanoparticle, MRI, Incidence, Liver, U.S. FDA, Liver cancer, Hepatocellular carcinoma, News, IND, Journal, Safety, FDA, Finance, Kidney, Clinical trial, Phase, Colorectal cancer, Biopsy, Diagnosis, Magnetic resonance imaging, JMRI, Cancer, Medical imaging

MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.

Key Points: 
  • MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.
  • Applications to the FDA for global phase III clinical trials are expected to take place in the second quarter of 2024.
  • Megapro states that the diagnosis of focal liver lesion by contrast-enhanced MRI remained an important clinical needs globally.
  • Therefore, MegaPro plans to further develop the MPB1523, nano-iron oxide MRI contrast agent, for its phase 3 study.

The Global Market for Nanotechnology and Nanomaterials 2024-2034: In-Depth Analysis and Sustainability Insights Propel Industry Forward - ResearchAndMarkets.com

Retrieved on: 
Monday, January 15, 2024
Sustainability, Technology, Nanotechnology, Environment, Carbon, 2D, Aviation, Lighting, Nanoparticle, Lubricant, Food, Agriculture, Electronics, TRL, Mining, Medicine, Market, Cosmetics, Adhesive, Textile, Water, 3D, Television, Health, Quantum, Filtration, Nanocellulose, Table tennis rubber, Dendrimer, Landing slot, Environmental remediation

Their use is only going to increase due to continued industry demand for nanomaterials for current and next generation batteries, biomedical imaging and flexible electronics.

Key Points: 
  • Their use is only going to increase due to continued industry demand for nanomaterials for current and next generation batteries, biomedical imaging and flexible electronics.
  • The Global Market for Nanotechnology and Nanomaterials 2024-2034 is an in-depth analysis of the opportunities afforded by these remarkable materials and technologies.
  • In-depth analysis of the global market for nanotechnology and engineered nanomaterials based products.
  • Assessment of end user markets for nanotechnology and Engineered nanomaterials including market drivers and trends, applications, market opportunity, market challenges and application and product developer profiles.

Going Beyond Plastic: Chung-Ang University Team Explores Tara Gum as a Green Polymer

Retrieved on: 
Tuesday, January 16, 2024
Seed, Nanoparticle, Research, Toxicology, Food, Polysaccharide, D-3, Behavior, Administration, Plastic, Chung-Ang University, Edible, Zinc, Safety, Chitosan, Food industry, Copper, Carbohydrate Polymers, South Korea, Pollution, Gum arabic

SEOUL, South Korea, Jan. 16, 2024 /PRNewswire/ -- Synthetic, non-biodegradable plastics are major sources of environmental pollution and have prompted a rising interest in sustainable, biodegradable alternatives derived from natural polymers. "Tara gum," derived from the seeds of the tara tree (Caesalpinia spinosa), stands out as a promising solution. This natural, water-soluble substance contains polysaccharides (complex carbohydrates), including the widely used "galactomannan," which is employed in coatings, edible films, and as a stabilizer and thickener. The biocompatibility, biodegradability, and safety of tara gum also make it valuable in industries like food and drug delivery. Moreover, the adaptable nature of the groups within tara gum polysaccharides renders it valuable for tailoring physicochemical and mechanical properties for specific applications.

Key Points: 
  • "Tara gum," derived from the seeds of the tara tree (Caesalpinia spinosa), stands out as a promising solution.
  • The biocompatibility, biodegradability, and safety of tara gum also make it valuable in industries like food and drug delivery.
  • Moreover, the adaptable nature of the groups within tara gum polysaccharides renders it valuable for tailoring physicochemical and mechanical properties for specific applications.
  • "The physicochemical property of tara gum and its products can be enhanced using various kinds of monomers, crosslinkers, or other polysaccharides.

Gauzy, Research Frontiers and LG Display Reveal at 2024 CES Show How to Make Transparent OLEDs Even Better by Integrating Research Frontiers SPD-Smart Film Technology

Retrieved on: 
Wednesday, January 10, 2024
Transport, Nanoparticle, OLED, Research Frontiers, Glass, SPD, Car, Electronics, Environment, GLARE, Safety, CES, System, Transparency, LG Display, Light, Research, Consumer electronics, Television

In a collaboration among Gauzy, LG Display, and Research Frontiers, the fusion of SPD-Smart film and Transparent OLED screens is ushering in a new era of display innovation.

Key Points: 
  • In a collaboration among Gauzy, LG Display, and Research Frontiers, the fusion of SPD-Smart film and Transparent OLED screens is ushering in a new era of display innovation.
  • Debuting for the first time, at Gauzy’s booth, there will be a 30-inch, LG Display Transparent OLED integrating SPD-Smart film.
  • The 30-inch LG Display Transparent OLED product demonstrates some of the more widely known applications of Transparent OLED, including window displays in railway, retail, and entertainment systems.
  • The combination of SPD-Smart film and Transparent OLED displays marks a significant leap forward in display technology, unlocking innovative possibilities for a wide range of applications.

SOHM Files Provisional Patent on ABBIE’s ‘Smart Gene-Editing’ That Uses Latest Enzymes and Guide RNA to Resolve Off-Target Gene-Editing Limitations

Retrieved on: 
Tuesday, January 9, 2024
Nanoparticle, Health, DNA, Agriculture, Graphene, Medicine, Communication, Risk, Safety, Cell engineering, FDA, Genome, Point-of-care testing, Cell, Vaccine

SOHM’s developers have recently submitted a provisional patent application detailing technology designed to more tightly control editing events.

Key Points: 
  • SOHM’s developers have recently submitted a provisional patent application detailing technology designed to more tightly control editing events.
  • This patent pending ABBIE technology will leverage effector molecules, such as kinases and phosphatases, to regulate the activity of engineered DNA at a target site.
  • ABBIE will also utilize advances in graphene-based nanomaterials, nano sensors, and wireless communication technologies allowing for enhanced control and fine-tuning of the gene editing process.
  • SOHM has filed a provisional patent application on its innovative technology.

Global Nanotechnology Market Poised to Reach $183.7 Billion by 2028, According to BCC Research Analysis

Retrieved on: 
Thursday, January 11, 2024
Private, Healthcare industry, Field line, Nanoparticle, Research, Growth, Nanomedicine, Investment, Science, Electronics, BCC, Administration, Nanomaterials, Solid-state drive, Transport, Nanosensor, Row, Energy, Renewable energy

BOSTON, Jan. 11, 2024 /PRNewswire/ -- The global nanotechnology market is experiencing robust growth, propelled by continuous advancements in science and technology that enable the manipulation of matter at the nanoscale. This market, characterized by the development, production, and commercialization of nanotechnology-based products, has witnessed widespread applications across diverse industries. Nanomaterials, including nanoparticles and nanostructured materials, serve as the building blocks for innovations in electronics, healthcare, energy, and materials science. Specialized nanotools and instruments, such as scanning probe microscopes and electron microscopes, facilitate the study and manipulation of materials at the nanoscale. Nanodevices, ranging from Nanosensors to nanomedicine solutions, showcase the transformative potential of nanotechnology. Government initiatives, increased research and development activities, and collaborations between academia and industry contribute to the market's growth. Despite challenges related to regulation and public perception, the outlook for the global nanotechnology market remains promising, driven by ongoing technological breakthroughs and the integration of nanotechnology into a myriad of applications.

Key Points: 
  • According to the latest BCC Research study, the demand for Global Nanotechnology Market is estimated to increase from $68.0 billion in 2023 to reach $183.7 billion by 2028, at a compound annual growth rate (CAGR) of 22.0% from 2023 through 2028.
  • Despite challenges related to regulation and public perception, the outlook for the global nanotechnology market remains promising, driven by ongoing technological breakthroughs and the integration of nanotechnology into a myriad of applications.
  • This report delves into the nanotechnology industry , offering comprehensive estimates and forecasts for the global market.
  • The report narrows its attention to the global nanotechnology market, categorizing it by types such as Nanosensors, nanodevices, and nanomaterials, among others.